Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 20/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005289 | 1.00 | SLC22A2 (0.66) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL81213 | 1.00 | SLC22A2 (0.66) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19327615 | 1.00 | SLC22A2 (0.66) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19739112 | 1.00 | SLC22A2 (0.66) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17748225 | 0.93 | SLC22A2 (0.58) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19056187 | 0.90 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL80386 | 0.90 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29775493 | 0.90 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL18424163 | 0.88 | SLC22A2 (0.74) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22584743 | 0.88 | SLC22A2 (0.74) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20190284208-A1 | N-[(2,4-DIFLUOROPHENYL)METHYL]-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-CARBOXAMIDE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2019-09-19 | — | — | US | disclosed |
| EP-3045206-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284208-A1 | N-[(2,4-DIFLUOROPHENYL)METHYL]-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-CARBOXAMIDE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NR4A2, NR4A3 | SLC22A2 3802/4885CYP3A4 22/4885TMEM97 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.